As the world continues to adapt to a new way of life due to the COVID-19 pandemic, Cumberland continues to take action to protect our employees, secure our supply chain and support the patients who can benefit from our medicines. Our office is open and we continue to operate our business while maintaining compliance with the many laws and regulations we fall under.


Our focus this year remains on our three catalysts:

- Contributions from our Vibativ® acquisition

- Introduction of our next generation Caldolor® product

- Preparations for the launch of our new RediTrex® product line


We will also continue to develop our pipeline of drugs, including the candidates emerging from Cumberland Emerging Technologies (CET).


During the second quarter of 2020, we implemented three national initiatives to help medical facilities treat patients with conditions associated with COVID-19 infections, including pneumonia, high fevers and electrolyte imbalances. Through these initiatives, we offered special supply and financial arrangements for our three acute care brands:  Caldolor®, Vaprisol® and Vibativ®.


Additionally, we announced several significant publications featuring Vibativ:


- Two papers detailed the sustained potency and excellent activity against drug-resistant bacteria, such as MRSA, through a 7-year antimicrobial surveillance program. Learn more here.

- Another study detailed the positive real-world clinical outcomes with Vibativ in treating patients with bacteremia (bacteria in the blood) and endocarditis (heart chamber infections). Learn more here.

We continue to make progress toward our goal of building a speciality pharmaceutical business that delivers sustained growth, profitable operations and long-term value. We would like to give a special thanks to our team for their efforts in the first half of 2020 and remain focused on our mission of advancing patient care through the delivery of high-quality medicines. Stay safe and healthy.